Exogenous Toxicants and Genetic Susceptibility in ALS
NCT00011154 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 525
Last updated 2006-03-23
Summary
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative disease that poses a significant burden for affected individuals and their family members. The principal objective of this epidemiologic study is to identify environmental and genetic risk factors for ALS. Of primary interest is whether environmental chemicals such as heavy metals, pesticides and organic solvents contribute to the cause of ALS. We also aim to identify genetic factors that contribute to the risk of ALS because individuals with certain genetic traits may be unable to protect against the toxic effects of chemical exposure. Other factors that may protect against the development of ALS, such as dietary antioxidants, are also under investigation. If modifiable factors affecting the risk for ALS could be identified, interventions to delay or even prevent the development of ALS could be developed.
Conditions
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 1996-09-30
- Completion
- 2002-08-31
More Related Trials
-
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders
NCT05474235 ·Status: RECRUITING
-
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
NCT03324399 ·Status: COMPLETED ·Phase: NA
-
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
NCT05137665 ·Status: RECRUITING
-
Safety Extension Study of TRO19622 in ALS
NCT01285583 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS)
NCT05107349 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT07082192 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
NCT05349721 ·Status: TERMINATED ·Phase: PHASE2
-
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
NCT02228915 ·Status: COMPLETED
-
Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)
NCT00231140 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS
NCT05852405 ·Status: COMPLETED
-
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis
NCT00005766 ·Status: COMPLETED ·Phase: PHASE2
-
Environmental Exposure and Neurological Diseases Questionnaire
NCT02916966 ·Status: COMPLETED
-
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03580616 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis
NCT05974579 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety Study of High Doses of Zinc in ALS Patients
NCT01259050 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Determining the Safety of L-serine in ALS
NCT01835782 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS
NCT07312240 ·Status: RECRUITING ·Phase: NA
-
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
NCT01091142 ·Status: COMPLETED ·Phase: PHASE1
-
New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.
NCT03984708 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Determinants of Disease Severity in Amyotrophic Lateral Sclerosis
NCT00004457 ·Status: UNKNOWN
-
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
NCT05053035 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT06215755 ·Status: TERMINATED ·Phase: PHASE1
-
Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis
NCT04518540 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Tazbentetol in ALS Participants
NCT07325591 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3